Davy James

In clinical trials, bepirovirsen was found to recognize the RNA used by hepatitis B virus to replicate in infected liver cells.

Eohilia, a corticosteroid developed specifically to treat eosinophilic esophagitis, is comprised of a novel formulation of budesonide taken twice daily for 12 weeks in patients 11 years of age and older.

JNJ-2113, a novel, oral IL-23–receptor antagonist peptide showed significant efficacy in patients with moderate-to-severe plaque psoriasis compared with placebo.

The FDA placed a full clinical hold on magrolimab for hematologic cancers after data showed the drug in combination with azacitidine plus Venclexta increased the risk of death related to infections and respiratory failure in patients with acute myeloid leukemia.

Data suggest that dosing of MariTide may be effectively tapered down and the drug may be taken less frequently over time compared with GLP-1 agonists such as Wegovy and Zepbound.

Phase III CheckMate -77T trial data show statistically significant improvements in event-free survival with Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo in the treatment of resectable stage IIA to IIIB non-small cell lung cancer.

BioNTech SE and Duality Biologics Co's BNT325/DB-1305 is a next-generation antibody-drug conjugate that targets the TROP2 protein, which is overexpressed across various tumor types.

Arexvy was the first FDA-approved respiratory syncytial virus (RSV) vaccine to prevent lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

UV1 is an off-the-shelf vaccine that has demonstrated a survival benefit in combination with ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with unresectable malignant pleural mesothelioma.

New reservation program for Beyfortus (nirsevimab-alip) seeks to improve access to the monoclonal antibody that is FDA-approved to protect against respiratory syncytial virus-associated lower respiratory tract disease.

Allarity reached an agreement with Novartis in 2018 to license dovitinib, a small molecule multi-tyrosine kinase inhibitor under evaluation for the treatment of renal cell carcinoma.

Treatment with the novel engineered T-cell receptor produced an overall response rate of about 39% in patients with heavily pretreated synovial sarcoma.

BST02 is a novel cell-based immunotherapy currently being evaluated in a Phase I trial for the treatment of all types of liver cancer.

Vabysmo, the first bispecific antibody approved by the FDA for ocular conditions, produced significant drying of retinal fluid, which is often associated with blurry vision.

Biogen and partner Eisai will shift focus to advancing Leqembi, the first anti-amyloid beta treatment for Alzheimer disease to be granted traditional approval by the FDA.